or

Wheat Pit Sep '22 (WU22)

853-6s unch (unch) 09/15/22 [CBOT]
N/A x N/A N/A x N/A
underlying price ()
Quote Overview for Thu, Sep 15th, 2022
Day Low
853-6
Day High
853-6
Open 853-6
Previous Close 853-6 853-6
Volume 33 33
Open Interest 30 30
Stochastic %K 95.81% 95.81%
Weighted Alpha +5.25 +5.25
5-Day Change +43-2 (+5.34%) +43-2 (+5.34%)
52-Week Range 695-2 - 1278-6 695-2 - 1278-6
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure

Wheat (Pit) Futures Market News and Commentary

Wheat Pressure Continues as Wet Forecast Covers US

Wheat is trading with midday losses across the three markets on Wednesday. Chicago SRW futures are down 6 to 7 cents so far on the day. Kansas City HRW contracts is 7 to 8 cents in the red at midday.  MPLS spring wheat is slipping 4 to 6 cents so far on the session.

The next few days shows precipitation across much of the US, with much of the area from the Rockies to the Appalachians expecting at least an inch. Heavier total are seen in eastern KS, OK, and western MO. 

The US dollar index back up $0.800 to $99.485 so far on Wednesday, following the strength from Tuesday and putting some pressure on the market. 

Overnight, South Korean mills purchased 50,000 MT of wheat from the US. 

May 25 CBOT Wheat  is at $5.28 1/2, down 7 cents,

Jul 25 CBOT Wheat  is at $5.43 3/4, down 6 1/2 cents,

May 25 KCBT Wheat  is at $5.38 3/4, down 7 1/4 cents,

Jul 25 KCBT Wheat  is at $5.51, down 7 1/4 cents,

May 25 MGEX Wheat  is at $5.90 1/2, down 5 cents,... Read more

Contract Specifications

See More
Contract
Chicago Soft Red Winter Wheat [Pit]
Contract Size
5,000 bushels
Tick Size
1/4 cent per bushel ($12.50 per contract)
Trading Hours
8:30a.m. - 1:15p.m. CST
Exchange
CBOT
Point Value
$50
Expiration Date
09/14/22 (expired)

Seasonal Chart

Wheat Pit Sep '22
Average Price Chart for 5 Prior Pit Contracts
Get Realtime - Quotes and Charts for Futures Traders. Learn More >>

Price Performance

See More
Period Period Low Period High Performance
1-Month
731-4 +16.71%
on 08/18/22
Period Open: 800-6
853-6 unch
on 09/15/22
+53-0 (+6.62%)
since 08/15/22
3-Month
731-4 +16.71%
on 08/18/22
Period Open: 1063-4
1090-4 -21.71%
on 06/16/22
-209-6 (-19.72%)
since 06/15/22
52-Week
695-2 +22.80%
on 09/21/21
Period Open: 711-6
1278-6 -33.24%
on 05/17/22
+142-0 (+19.95%)
since 09/15/21

More Wheat (Pit) Quotes

All Futures Prices
Please wait...
Please wait...
false

Most Recent Stories

More News
Shootin' the Bull about hindsight

Still kicking the same dead horse, but this time with a little more enthusiasm.

Corn Facing Midweek Pressure

The corn market is holding onto Wednesday losses so far at midday. Contracts are down 2 to 4 cents. The front month CmdtyView national average Cash Corn price is down 2 ¾ cents at $4.46 3/4. Weekly EIA...

ZCZ25 : 454-4s (-0.76%)
ZCPAUS.CM : 4.4483 (-0.81%)
ZCPZ25US.CM : 4.2136 (-0.87%)
ZCK25 : 472-0s (-0.79%)
ZCN25 : 479-2s (-0.83%)
Wheat Pressure Continues as Wet Forecast Covers US

Wheat is trading with midday losses across the three markets on Wednesday. Chicago SRW futures are down 6 to 7 cents so far on the day. Kansas City HRW contracts is 7 to 8 cents in the red at midday. ...

KEN25 : 550-2s (-1.43%)
MWK25 : 591-4s (-0.67%)
KEK25 : 537-6s (-1.51%)
ZWK25 : 528-2s (-1.35%)
ZWN25 : 543-4s (-1.23%)
Soybean Bulls Gaining Ground on Wednesday

The soybean market is trading with gains of 2 to 6 cents so far on Wednesday, led by the front months. CmdtyView’s national front month Cash Bean price is up 6 1/4 cents at $9.91 1/2. Soymeal futures...

ZSPX25US.CM : 9.6447 (+0.09%)
ZLN25 : 48.34s (+0.65%)
ZMN25 : 298.6s (-0.30%)
ZSPAUS.CM : 9.9040 (+0.53%)
ZSK25 : 1040-2s (+0.51%)
ZSX25 : 1027-4s (+0.10%)
ZSN25 : 1050-2s (+0.41%)
Grain Markest Mixed Wednesday Morning

Grain markets have been mixed in the overnight and early morning trade. Soybeans were initially higher overnight on trade headlines, but have given back some of that ground

The Sinclair Report April 23, 2025: Grain Markets Overview

Wheat (ZWN25): The market broke through a critical support level set on August 27, 2024, at 560. This breakdown led to a short entry at 560 on April 21, with downside targets now seen at 545, 533, and...

Wheat Slide Continuing on Wednesday

Wheat is trading with mostly weaker action so far on Wednesday morning. The wheat complex was weaker across the three market on Tuesday. Chicago SRW futures posted 2 to 3 cent losses on the day. Kansas...

KEN25 : 550-2s (-1.43%)
MWK25 : 591-4s (-0.67%)
KEK25 : 537-6s (-1.51%)
ZWK25 : 528-2s (-1.35%)
ZWN25 : 543-4s (-1.23%)
Corn Weakness Leaking into Wednesday

The corn market is heading lower on Wednesday, with losses of 2 to 3 cents so far on Wednesday morning. Corn futures ended the Tuesday session with contracts down 6 to 7 cents. New crop December was down...

ZCZ25 : 454-4s (-0.76%)
ZCPAUS.CM : 4.4483 (-0.81%)
ZCPZ25US.CM : 4.2136 (-0.87%)
ZCK25 : 472-0s (-0.79%)
ZCN25 : 479-2s (-0.83%)
Soybeans Holding Near Steady Early on Wednesday

The soybean market is trading with contracts mixed, as front months are slightly higher and new crop slightly lower. Soybean futures popped higher on Tuesday, with contracts fractionally to 6 cents higher,...

ZSPX25US.CM : 9.6447 (+0.09%)
ZLN25 : 48.34s (+0.65%)
ZMN25 : 298.6s (-0.30%)
ZSPAUS.CM : 9.9040 (+0.53%)
ZSK25 : 1040-2s (+0.51%)
ZSX25 : 1027-4s (+0.10%)
ZSN25 : 1050-2s (+0.41%)
Did Watson Overshoot in the Soybean Market?

When making an investment decision about any market, it pays to understand that market's structure. Each market has two sides: Commercial and noncommercial, the latter also known as Watson.

ZSN25 : 1050-2s (+0.41%)
$CNSI : 983.02 (+0.70%)
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

FATE : 1.3300 (-2.92%)
Fate Therapeutics Reports Positive Phase 1 Results for FT819 in Lupus Treatment with Favorable Safety Profile and Initiates Dose Expansion

Fate Therapeutics reports positive results from FT819 study in lupus, showing effective B-cell depletion and favorable safety outcomes.Quiver AI SummaryFate Therapeutics, Inc. announced promising results...

FATE : 1.3300 (-2.92%)
Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus

FATE : 1.3300 (-2.92%)
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

FATE : 1.3300 (-2.92%)
Fate Therapeutics Announces Leadership Transition as Bob Valamehr, Ph.D. MBA, to Succeed Scott Wolchko as President and CEO Effective January 1, 2025

Bob Valamehr will become CEO of Fate Therapeutics on January 1, 2025, succeeding retiring Scott Wolchko.Quiver AI SummaryFate Therapeutics, a clinical-stage biopharmaceutical company focused on induced...

FATE : 1.3300 (-2.92%)
Fate Therapeutics Announces Leadership Transition

FATE : 1.3300 (-2.92%)
Fate Therapeutics to Present at Upcoming December Investor Conferences

FATE : 1.3300 (-2.92%)
FATE Presents Encourgaing Data From Lupus Study, Stock Gains

Fate Therapeutics, Inc. FATE presented encouraging initial clinical and translational data from the first patient treated in its early-stage study on experimental pipeline candidate  FT819.Data showed...

IMCR : 29.80 (+0.95%)
CSTL : 21.27 (-3.23%)
FATE : 1.3300 (-2.92%)
SPRO : 0.7271 (-0.70%)
Fate Therapeutics Reports Successful Clinical Remission in First Patient Treated with FT819 for Lupus Nephritis

A lupus nephritis patient achieved clinical remission after FT819 treatment, showing promising safety and immune reset outcomes. Quiver AI SummaryFate Therapeutics, Inc. announced promising results from...

FATE : 1.3300 (-2.92%)
Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR Convergence

FATE : 1.3300 (-2.92%)
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

FATE : 1.3300 (-2.92%)
Fate Therapeutics Reports Positive Phase 1 Results for FT819 in Lupus Treatment with Favorable Safety Profile and Initiates Dose Expansion

Fate Therapeutics reports positive results from FT819 study in lupus, showing effective B-cell depletion and favorable safety outcomes.Quiver AI SummaryFate Therapeutics, Inc. announced promising results...

FATE : 1.3300 (-2.92%)
Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus

FATE : 1.3300 (-2.92%)
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

FATE : 1.3300 (-2.92%)
Fate Therapeutics Announces Leadership Transition as Bob Valamehr, Ph.D. MBA, to Succeed Scott Wolchko as President and CEO Effective January 1, 2025

Bob Valamehr will become CEO of Fate Therapeutics on January 1, 2025, succeeding retiring Scott Wolchko.Quiver AI SummaryFate Therapeutics, a clinical-stage biopharmaceutical company focused on induced...

FATE : 1.3300 (-2.92%)
Fate Therapeutics Announces Leadership Transition

FATE : 1.3300 (-2.92%)
Fate Therapeutics to Present at Upcoming December Investor Conferences

FATE : 1.3300 (-2.92%)
FATE Presents Encourgaing Data From Lupus Study, Stock Gains

Fate Therapeutics, Inc. FATE presented encouraging initial clinical and translational data from the first patient treated in its early-stage study on experimental pipeline candidate  FT819.Data showed...

IMCR : 29.80 (+0.95%)
CSTL : 21.27 (-3.23%)
FATE : 1.3300 (-2.92%)
SPRO : 0.7271 (-0.70%)
Fate Therapeutics Reports Successful Clinical Remission in First Patient Treated with FT819 for Lupus Nephritis

A lupus nephritis patient achieved clinical remission after FT819 treatment, showing promising safety and immune reset outcomes. Quiver AI SummaryFate Therapeutics, Inc. announced promising results from...

FATE : 1.3300 (-2.92%)
Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR Convergence

FATE : 1.3300 (-2.92%)
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

FATE : 1.3300 (-2.92%)
Fate Therapeutics Reports Positive Phase 1 Results for FT819 in Lupus Treatment with Favorable Safety Profile and Initiates Dose Expansion

Fate Therapeutics reports positive results from FT819 study in lupus, showing effective B-cell depletion and favorable safety outcomes.Quiver AI SummaryFate Therapeutics, Inc. announced promising results...

FATE : 1.3300 (-2.92%)
Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus

FATE : 1.3300 (-2.92%)
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

FATE : 1.3300 (-2.92%)
Fate Therapeutics Announces Leadership Transition as Bob Valamehr, Ph.D. MBA, to Succeed Scott Wolchko as President and CEO Effective January 1, 2025

Bob Valamehr will become CEO of Fate Therapeutics on January 1, 2025, succeeding retiring Scott Wolchko.Quiver AI SummaryFate Therapeutics, a clinical-stage biopharmaceutical company focused on induced...

FATE : 1.3300 (-2.92%)
Fate Therapeutics Announces Leadership Transition

FATE : 1.3300 (-2.92%)
Fate Therapeutics to Present at Upcoming December Investor Conferences

FATE : 1.3300 (-2.92%)
FATE Presents Encourgaing Data From Lupus Study, Stock Gains

Fate Therapeutics, Inc. FATE presented encouraging initial clinical and translational data from the first patient treated in its early-stage study on experimental pipeline candidate  FT819.Data showed...

IMCR : 29.80 (+0.95%)
CSTL : 21.27 (-3.23%)
FATE : 1.3300 (-2.92%)
SPRO : 0.7271 (-0.70%)
Fate Therapeutics Reports Successful Clinical Remission in First Patient Treated with FT819 for Lupus Nephritis

A lupus nephritis patient achieved clinical remission after FT819 treatment, showing promising safety and immune reset outcomes. Quiver AI SummaryFate Therapeutics, Inc. announced promising results from...

FATE : 1.3300 (-2.92%)
Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR Convergence

FATE : 1.3300 (-2.92%)

Barchart Trading Guide

The Barchart Trading Guide is a Buy Signal with a Soft Signal Strength.

Key Turning Points

3rd Resistance Point 853-6
2nd Resistance Point 853-6
1st Resistance Point 853-6
Last Price 853-6s
1st Support Level 853-6
2nd Support Level 853-6
3rd Support Level 853-6

See More

52-Week High 1278-6
Fibonacci 61.8% 1055-7
Fibonacci 50% 987-0
Fibonacci 38.2% 918-1
Last Price 853-6s
52-Week Low 695-2

See More

Solutions for Grain Market Professionals barchart.com/cmdty
Commodity Price Reports
Get Free Access!
cmdtyView for Ag marketers and merchandisers
Start Free Trial
We help Agribusinesses make better decisions
Learn Now
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Value Investing Philosophies: Graham, Buffett, Bogle, and EMH in Perspective

Info When You Need It Most.

Barchart Premier is one of the most powerful tools in the investment world. Come see why so many subscribers love it — and try it risk-free for 30 days.